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ORIGINAL ARTICLE
Non-sentinel lymph node involvement in patients with
breast cancer and sentinel node micrometastasis; too
early to abandon axillary clearance
M A den Bakker, A van Weeszenberg, A Y de Kanter, F H Beverdam, C Pritchard,
Th H van der Kwast, M Menke-Pluymers
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Aims: It has been suggested that patients with T1–2 breast tumours and sentinel node (SLN) microme-
tastases, defined as foci of tumour cells smaller than 2 mm, may be spared completion axillary lymph
node dissection because of the low incidence of further metastatic disease. To gain insight into the
extent of non-sentinel lymph node (n-SLN) involvement, SLNs and complementary axillary clearance
specimens in patients with SLN micrometastases were examined.
Methods: A set of 32 patients with SLN micrometastases was selected on the basis of pathology
reports and review of SLNs. Five hundred and thirteen n-SLNs from the axillary clearance specimens
were serially sectioned and analysed by means of immunohistochemistry for metastatic disease. Lymph
node metastases were grouped as macrometastases (> 2 mm), and micrometastases (< 2 mm), and
further subdivided as isolated tumour cells (ITCs) or clusters.
Results: In 11 of 32 patients, one or more n-SLN was involved. Grade 3 tumours and tumours > 2 cm
(T2–3 v T1) were significantly associated with n-SLN micrometastases as clusters (grade: odds ratio
(OR), 8.3; 95% confidence interval (CI), 1.4 to 50.0; size: T2–3 tumours v T1: OR, 15; 95% CI, 2.18
to 103.0). However, no subgroup of tumours with regard to size and grade was identified that did not
have n-SLN metastases.
Conclusions: In patients with breast cancer and SLN micrometastases, n-SLN involvement is relatively
common. The incidence of metastatic clusters in n-SLN is greatly increased in patients with T2–3
tumours and grade 3 tumours. Therefore, axillary lymph node dissection is especially warranted in
these patients. However, because n-SLN metastases also occur in T1 and low grade tumours, even
these should be subjected to routine axillary dissection to achieve local control.
The sentinel node procedure was pioneered for penilecarcinoma.1 In recent years, it has been introduced forbreast cancer, where its main purpose is to gain insight
into the status of the axillary basin for the presence of meta-
static disease.2 3 Axillary clearance with its associated morbid-
ity can be avoided if metastatic disease in the SLN cannot be
proved. To rely on the SLN procedure in guiding patient man-
agement, it is essential that it be thoroughly investigated.
Many studies have clearly shown that more sensitive
techniques such as serial sectioning, the use of immunohisto-
chemistry, and molecular techniques (such as reverse tran-
scription polymerase chain reaction) dramatically increase the
detection rate of metastatic disease in lymph nodes.4–10 A direct
consequence of this enhanced sensitivity is the observed
increased incidence of micrometastatic and “occult” disease.
Although not all studies agree on this, several papers showed
a survival disadvantage for patients with micrometastatic
disease.6 11–13
In addition to its application as a staging procedure in guid-
ing further treatment, it has been suggested that the SLN pro-
cedure may in certain circumstances serve a secondary func-
tion as ameans of local disease control by removingmetastatic
disease.14 15 In this setting, it is assumed that the SLN has
effectively filtered out early metastatic disease before tumour
microemboli have had the chance to spread beyond the initial
lymph node. Furthermore, it is assumed by some that certain
forms of micrometastatic disease, such as isolated tumour
cells, may not have the potential for outgrowth.4 16 Accepting
these hypotheses implies that metastatic disease in n-SLNs
should only rarely be found in cases with SLN micrometas-
tases. To test these assumptions we examined the n-SLNs of
patients with micrometastatic SLN disease.
“It has been suggested that the sentinel lymph node pro-
cedure may in certain circumstances serve a secondary
function as a means of local disease control by removing
metastatic disease”
METHODS
Identification of the sentinel node was performed by
peritumoral injection of 40 MBq (99m)Tc radiolabelled nano-
colloid at least 2.5 hours before surgery and intradermal
injection of 0.5 ml patent blue dye during surgery. The sentinel
node was identified with the guidance of the RMD-CTC4
probe (Radiation Monitoring Devices, Watertown, Maine,
USA), aided by visual identification of the blue stained vessel,
and was removed under general anaesthesia. After frozen sec-
tion analysis (superficial level of one half of a bisected lymph
node), the remaining SLN tissue was formalin fixed and par-
affin wax embedded. Large nodes were trimmed down into
smaller pieces and submitted in toto for histology. Sections
were cut at four 250 µm intervals with parallel haematoxylin
and eosin (H&E) and immunohistochemical (IHC) staining
with anticytokeratin antibodies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: CI, confidence interval; H&E, haematoxylin and eosin;
IHC, immunohistochemistry; ITC, isolated tumour cell; LN, lymph node;
n-SLN, non-sentinel lymph node; OR, odds ratio; SLN, sentinel lymph
node
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On the basis of pathology reports, 40 patients were
identified who had an SLN micrometastasis. The SLNs and
primary tumours of these patients were reviewed. Grading of
the primary tumours was performed according to the
modified Bloom and Richardson criteria.17 The sizes of the SLN
and n-SLN micrometastases were measured on the micro-
scope stage using the Vernier scale; in equivocal cases, a digital
image was acquired and measurements were made using an
image analysis application (AutoCyte Link; TriPath Imaging
Inc, Burlington, North Carolina, USA). Metastases were
divided into three groups, namely: metastases larger than
2 mm (macrometastases); micrometastases (< 2 mm) con-
sisting of groups of four or more cells in close approximation,
termed clusters; and micrometastases consisting of isolated
single tumour cells or small collections of up to three tumour
cells together, designated as isolated tumour cells (ITCs).16
Whenmultiple micrometastases were present in a single node,
the largest metastasis was measured. The sizes of individual
metastases were not added together. After reviewing the
SLNs, eight patients were excluded from our study (in seven
patients the metastasis was over 2 mm in size, one patient did
not proceed to axillary node dissection). The remaining 32
patients formed the basis of our study. From these patients, all
n-SLNs were cut at 250 µm intervals through the paraffin wax
block, resulting in three to 10 additional sections for each
block. The sections were immunostained with anticytokeratin
antibody CAM 5.2 (Becton Dickinson, Mountain View,
California, USA) using a standard peroxidase–anti-peroxidase
procedure in an automated immunostainer (Mark V; DPC, Los
Angeles, California, USA). Appropriate positive and negative
controls were incorporated in each run of the immunostainer.
In equivocal cases, H&E stained sections were prepared from
retained ribbons for comparison. The presence of micrometas-
tases was scored and compared with the tumour parameters
size and grade using the statistical package SPSS for Windows
release 10.05 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Thirty two patients with breast cancer were identified with a
SLN micrometastasis. Forty five SLNs were derived from these
patients, ranging from one to four lymph nodes (LNs)/patient
(median, one). The primary tumours were 27 ductal type
adenocarcinomas “not otherwise specified” and five lobular
carcinomas (table 1). Mean tumour size was 19 mm (range,
6–55 mm). The axillary clearances yielded 513 LNs (range,
3–28; median, 14). Because of the poor clinical condition of
one patient, only a limited (level 1) LN dissection was
performed, yielding four LNs. Metastases in n-SLNs were
identified in 24 of 513 LNs (4.7%) from the axilla of 11 of 32
patients, five of whom had initially been diagnosed as not
having n-SLN metastases (“occult metastases”) (table 2). In
addition to eight identified involved n-SLNs in the original
reports, 16 extra involved n-SLNs were documented after
serial sectioning and IHC. In two patients a macrometastasis
was found. Three patients had ITCs only, two patients only had
clusters (including one patient with a macrometastasis), and
six patients had ITCs and clusters (including one patient with
a macrometastasis). The number of involved n-SLNs ranged
from one to four (median, two). Within the group of 11
patients with n-SLN micrometastases, 10 carcinomas were of
the ductal type and the 11th case was a lobular carcinoma. The
mean tumour size in this group was 26.1 mm (range, 12–55).
Two of the carcinomas in this group were multifocal (multiple
non-continuous foci of invasive carcinoma, not necessarily
confined to one quadrant). In the group of 21 patients without
n-SLN micrometastases, the mean tumour size was 14.7 mm
(range, 6–35), 17 carcinomas were of the ductal type and four
tumours were lobular carcinomas. In this group of patients,
two patients had only ITCs in the SLN, two patients had ITCs
and clusters, and the remaining 17 patients had clusters.
The average tumour size was significantly larger in patients
with involved n-SLNs than in those without n-SLNmetastases
(26.1 mm (SD, 14.3) v 14.7 mm (SD, 7.2); t test, t = 2.474
(unequal variance); p = 0.028). The presence and type of
metastasis (ITC v cluster) of n-SLN metastases was analysed
with respect to tumour size and grade by calculating relative
odds (odds ratio; OR). A significantly greater risk of positive
n-SLNs with clusters was found for high grade tumours (OR,
8.3; 95% confidence interval (CI), 1. 4 to 50.0). The odds of
n-SLN metastases as clusters were significantly greater for
carcinomas > 2 cm (OR, 15; 95% CI, 2.18 to 103.0).
Table 1 Tumour characteristics of patient set
Positive n-SLN Negative n-SLN
No. of patients (%) 11 (34) 21 (66)
Primary tumour
Ductal 10 17
Lobular 1 4
Size (mm) 26.1 (median, 21) 14.7 (median, 12)
T1 3 19
T2 6 2
T3 2 0
Grade (Bloom and Richardson)
I 2 5
II 4 12
III 5 4
n-SLN, non-sentinel lymph node.
Table 2 Characteristics of tumours and results in 11 patients with n-SLN involvement
Patient No. of SLNs (pattern of involvement)
No. of
n-SLNs
Pattern of n-SLN
involvement (n)
Tumour
type
Size
(mm)
Grade
(B&R)
1 2 (SLN1 and SLN2 ITC) 19 ITC+ cluster (4)‡ Ductal 25 3
2 2 (SLN1 ITC+ cluster, SLN2−) 13 ITC (1) Lobular 50 1
3 1 (cluster) 8 Cluster* (3)‡ Ductal 12 1
4 1 (cluster) 22 Cluster (1) Ductal 21 3
5 1 (cluster) 10 ITC (1)‡ Ductal 17 2
6 1 (cluster) 11 Cluster* (2) Ductal 26 2
7 1 (cluster) 15 Cluster† + ITC (4) Ductal 30 3
8 3 (SLN1 cluster, SLN2 and SLN3−) 4 Cluster (2) Ductal 20 3
9 1 (cluster) 22 Cluster† (3) Ductal 21 2
10 1 (cluster) 10 ITC (1)‡ Ductal 55 2
11 1 (ITC+ cluster) 28 Cluster (2)‡ Ductal 10 3
*n-SLN micrometastasis larger than SLN metastasis; †n-SLN macrometastasis; ‡negative n-SLN status in
original report.
B&R, Bloom and Richardson; ITC, isolated tumour cell; nSLN, non-sentinel lymph node; SLN, sentinel lymph
node.
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DISCUSSION
The question arises whether the presence of microscopic
tumour deposits in the SLN justifies complete axillary
clearance and adjuvant treatment. It may be argued that for
staging purposes the object has been achieved by finding
metastatic disease in the SLN and that further involved nodes
are unlikely to be found.Moreover, the viewmay be taken that
removing an SLN with micrometastatic disease constitutes
adequate local control and that axillary clearance is not justi-
fied in these cases. Accepting this perspective implies that
either metastatic deposits in n-SLNs are highly unlikely or
that even if further micrometastatic deposits in n-SLNs are
present these will not result in locoregional disease.
To gain insight into possible metastatic disease in the
remaining (non-sentinel) axillary LNs we performed serial
sectioning with IHC on the n-SLNs of 32 patients with SLN
micrometastases. Metastases were grouped as macrometas-
tases (> 2 mm) and as micrometastases (< 2 mm).Microme-
tastases were further subdivided into “clusters” (four or more
cells together) and isolated tumour cells (single cells and
groups of up to three cells together).We found that in 11 of 32
patients metastatic disease was present in non-sentinel nodes
from the axilla, whereas in seven patients more than one node
was involved and in four patients the n-SLN metastasis was
larger than the SLN metastasis (including two patients with
n-SLN macrometastases). It is possible that erroneous SLN
identification had occurred in the patients with macrometas-
tases. Nevertheless, excluding these two patients does not sig-
nificantly detract from our observation that n-SLN involve-
ment is not uncommon when sensitive techniques are used.
Large n-SLN metastases in micrometastatic SLN involvement
have been noted previously, including n-SLN metastasis in
cases with single cells in the SLN.7
“On the basis of our findings and the literature data, we
find it premature to conclude that axillary dissection may
be avoided in patients with T1–2 tumours and sentinel
lymph node micrometastases, as suggested by Chu et al
and Reynolds et al”
In our study, LNs with radioactive tracer uptake were desig-
nated as SLNs, the blue dye served only as a visual aid in iden-
tification. Other workers have in some instances included
blue, non-radioactive nodes as SLNs, a practice that has been
challenged.18 19 From a conceptual viewpoint it could be argued
that there can only be a single “true” SLN and that all other
nodes are non-sentinel nodes. If this line of reasoning is pur-
sued, two of seven patients from our group without n-SLN
involvement would have to be considered as having n-SLN
involvement. Conversely, it has been shown that more than
one first echelon node (SLN) may be present. In accordance
with these observations we chose to accept multiple SLNs.
We found that n-SLNmetastases as clusters were associated
with tumours > 2 cm in size and with high grade tumours.
Other groups have not found tumour grade to be an
independent risk factor for n-SLN metastasis.18 20 21 This is sur-
prising, because grade has been shown to be associated with
an increased risk for nodal metastases in small tumours.22 23
The term micrometastasis has only been defined arbitrarily,
and its definition varies between studies. A cut off point of
2 mm has been used in many studies and is included in the
TNM classification.16 24 25 Alternatives, such as the area of
lymph node involved by tumour and the particular pattern of
lymph node involvement, have been suggested.19 26–28 The
importance of micrometastatic disease and the implications
for treatment when it is demonstrated hinge upon delineating
the biological behaviour of small tumour deposits and small
numbers of isolated tumour cells.12 Experimental studies sug-
gest that most isolated (circulating) tumour cells are not
viable and will not result in metastatic disease. Thus, in the
strictest sense, a micrometastasis requires the arrest of
tumour cells in the tissue and proliferation.4 16 Biological char-
acteristics such as viability, angiogenic capacity, and avoidance
of the host immune reaction may be equally important
factors.29 30 In addition, it may be necessary to look at the host
lymph node response, because this may also influence the
ability of a micrometastasis to expand.26 In this setting, it is
interesting to note that Colpaert et al found a survival advan-
tage for patients with SLN micrometastases and hypothesised
that this may result from an enhanced host immune
response.31
Whatever the outcome of single tumour cells in the circula-
tion or in organs may be, it should be appreciated that the very
fact that they are detected implies that access to the lymphat-
ics or blood vessels has been gained, and that a line of defence
has been breached in the metastatic pathway.
The incidence of n-SLN involvement varies in reports and
this is in part a result of the sensitivity of the detectionmethod
used. Naturally, more intensive analysis of LNs with serial sec-
tioning and immunohistochemistry will reveal more meta-
static disease, as has been shown in SLN research.9 10 Reynolds
et al did not observe n-SLN metastases in 18 patients with T1
tumours and micrometastases in the SLN. They propose that
axillary lymph node dissection may not be necessary in
patients with T1 breast tumours and SLN micrometastases.21
Likewise, Chu et al found that less than 5% of patients with T1
tumours and only 6% of patients with T1–2 tumours and
micrometastatic SLN disease had n-SLN involvement, and
they also suggest that axillary lymph node dissection may not
be necessary in these patients.18 20 However, the methods used
in their study, with one or two sections for each n-SLN and
without IHC, probably underestimated the extent of n-SLN
disease.20 The same investigators in Giuliano’s group later
found that 24% of patients with T1–2 tumours and microme-
tastases in the SLN (either detected by H&E staining or IHC)
harboured n-SLN metastases. In that study, two level IHC was
used, which may have increased the sensitivity. However, they
did find that when lymphatic vascular invasion and extran-
odal hilar tissue invasion were taken into account only one of
58 patients with T1–2 tumours had an n-SLN metastasis.32
Another study, examining n-SLN involvement in patients with
positive SLNs, found n-SLN involvement in 27% of patients
with a single SLN harbouring a metastasis < 1 mm.28 In our
series, three of 21 patients with T1 tumours and an SLN
micrometastasis had n-SLN metastases detected by serial sec-
tioning and IHC. On the basis of our findings and the
literature data,28 we find it premature to conclude that axillary
dissection may be avoided in patients with T1–2 tumours and
SLN micrometastases, as suggested by Chu et al and Reynolds
et al.18 20 21 Indeed, if n-SLN metastases are relatively common
in patients with micrometastatic SLN disease and are likely to
be followed by axillary node dissection, then it is imperative
that the SLN is meticulously investigated. Therefore, the ques-
tion that must be answered is how thoroughly this must be
done and at what cost.33 The ultimate test of the importance of
Take home messages
• Non-sentinel lymph node (n-SLN) involvement is relatively
common in patients with breast cancer and sentinel lymph
node micrometastases
• Metastatic clusters in n-SLN are found more frequently in
patients with T2–3 tumours and grade 3 tumours
• Thus, axillary lymph node dissection is especially war-
ranted in these patients, but because n-SLN metastases
occur even in T1 and low grade tumours, these tumours
should be subjected to routine axillary dissection to achieve
local control
• Further studies are needed with larger series and patient
follow up to assess the clinical relevance of these findings
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SLN micrometastatic disease and its treatment implications
will be disease recurrence and disease related survival. For this
issue to be resolved, further studies are needed with larger
series and patient follow up. A trial incorporating these
aspects organised by the oncology group of the American Col-
lege of Surgeons is under way.34
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